Hematology/Oncology

Top Story

Triplet chemotherapy may benefit intermediate-, poor-risk germ cell tumors

May 31, 2016

A chemotherapeutic triplet comprised of paclitaxel, ifosfamide and cisplatin exhibited efficacy as first-line treatment for patients with intermediate- or poor-risk germ cell tumors, according to the results of a prospective phase 2 study.

Germ cell tumors are considered a model of curable cancer, given their exquisite sensitivity to cisplatin-based chemotherapy, which allows durable complete responses to be achieved, even in the face of widely metastatic disease,” Darren R. Feldman, MD, urologic oncologist at Memorial Sloan Kettering Cancer Center, and colleagues wrote. “However, the likelihood of sensitivity to chemotherapy and cure varies significantly on the basis of clinical and pathologic factors, which have been incorporated into the International Germ Cell Cancer Collaborative Group prognostic model.”

Does chemotherapy cause cancer?

May 31, 2016
Patients with cancer who undergo chemotherapy may be at elevated risk for a new primary cancer several years later.The most common secondary cancers that occur in…
In the Journals

TP53 status may predict response to VEGFR inhibition for advanced sarcoma

May 31, 2016
The TP53 gene mutation may predict improved response to VEGF receptor inhibition among patients with advanced sarcomas, according to a retrospective chart review.Prior…
Meeting News Coverage

Top Takeaways from ASH: Mutations in MDS, AML impact prognosis, spur development of novel agents

May 30, 2016
Findings presented at the ASH Annual Meeting and Exposition contribute to the growing body of literature that demonstrates a correlation between specific gene mutations…

Model used to estimate link between radiation, cancer must be re-evaluated

May 29, 2016
Previous investigations conducted by the founders of the linear no-threshold model with respect to genetic effects and carcinogenesis represent “one of the…
More News Headlines »
CME Video

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Video
Meeting News Coverage

VIDEO: Expert discusses controversies in lung cancer screenings

May 13, 2016
More »
Featured
AACR Annual Meeting

AACR Annual Meeting

CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan
morganatic-roan